This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
DICE Therapeutics Beheer
Beheer criteriumcontroles 2/4
We currently do not have sufficient information about the CEO.
Belangrijke informatie
J. Judice
Algemeen directeur
US$5.8m
Totale compensatie
| Percentage CEO-salaris | 9.4% |
| Dienstverband CEO | 10yrs |
| Eigendom CEO | 1.7% |
| Management gemiddelde ambtstermijn | 2.6yrs |
| Gemiddelde ambtstermijn bestuur | 2.7yrs |
Recente managementupdates
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$104m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$6m | US$540k | -US$84m |
| Sep 30 2022 | n/a | n/a | -US$77m |
| Jun 30 2022 | n/a | n/a | -US$74m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$6m | US$465k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$40m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | US$637k | US$437k | -US$24m |
Compensatie versus markt: J.'s total compensation ($USD5.77M) is about average for companies of similar size in the US market ($USD5.11M).
Compensatie versus inkomsten: J.'s compensation has increased whilst the company is unprofitable.
CEO
J. Judice (59 yo)
10yrs
Tenure
US$5,773,577
Compensatie
Dr. J. Kevin Judice, Ph D., founded DiCE Molecules SV, Inc. (formerly known as DiCE Molecules Corp). and serves as its Chief Executive Officer, President and Secretary. Dr. Judice has extensive experience...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 10yrs | US$5.77m | 1.67% $ 38.0m | |
| Chief Business & Financial Officer | 5.7yrs | US$2.67m | 0.41% $ 9.4m | |
| Chief Medical Officer | 3yrs | US$2.72m | 0.32% $ 7.2m | |
| Chief Scientific Officer | 2.2yrs | US$714.79k | 0.31% $ 7.0m | |
| General Counsel | 1.4yrs | geen gegevens | geen gegevens | |
| Senior Vice President of CMC | 2.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Medicinal Chemistry | no data | geen gegevens | geen gegevens |
2.6yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: DICE's management team is considered experienced (2.6 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | no data | US$5.77m | 1.67% $ 38.0m | |
| Independent Director | 2.8yrs | US$264.90k | 0.10% $ 2.4m | |
| Independent Chairman of the Board | 7.7yrs | US$371.88k | 0.018% $ 400.6k | |
| Independent Director | 2.8yrs | US$264.90k | 0.086% $ 1.9m | |
| Independent Director | 1.4yrs | US$552.51k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$231.45k | geen gegevens | |
| Independent Director | 1.4yrs | US$552.51k | 0% $ 0 |
2.7yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: DICE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.